Combination of loteprednol and β
View Patent ↗The invention relates to a novel combination of a soft steroid, in particular loteprednol, and at least one β 2 adrenoceptor agonist for the simultaneous, sequential or separate treatment of allergies and/or airway disorders, medicaments comprising the combination, processes for the production of such medicaments and the use of the novel combination for the production of medicaments for the simultaneous, sequential or separate treatment of allergies and/or airway disorders.
1. A powdered pharmaceutical composition consisting essentially of
an efficacious amount of (i) loteprednol or loteprednol etabonate; and (ii) at least one β 2 adrenoreceptor agonist selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol, and pharmaceutically tolerable salts there of,
for administration by inhalation, wherein the pharmaceutical composition is formulated in a powdered form.
2. The powdered pharmaceutical composition according to claim 1 , consisting essentially of
(i) loteprednol or loteprednol etabonate; and
(ii) formoterol.
3. The powdered pharmaceutical composition according to claim 1 , consisting essentially of
(i) loteprednol or loteprednol etabonate, and
(ii) salmeterol.
4. The powdered pharmaceutical composition according to claim 1 , consisting essentially of
(i) loteprednol or loteprednol etabonate; and
(ii) reproterol.
5. A method for the treatment of asthma bronchiale in a patient, the method comprising:
administering to the patient an efficacious amount of (i) loteprednol or loteprednol etabonate and (ii) at least one β 2 adrenoceptor agonist selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol, and pharmaceutically tolerable salts there of,
wherein a pharmaceutically acceptable excipient or a vehicle is added.
6. A process for the preparation of a pharmaceutical composition for the treatment of asthma bronchiale, the process comprising:
combining (i) an effective amount of the active compound loteprednol or loteprednol etabonate and (ii) an effective amount of at least one β 2 adrenoceptor agonist selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol, and pharmaceutically tolerable salts there of,
wherein the loteprednol or loteprednol etabonate and one or more β 2 adrenoceptor agonists are mixed individually or together,
wherein a pharmaceutically acceptable excipient or a vehicle is added, and
wherein the composition thus obtained is converted into a powdered form suitable for inhalations.